SCHEMBL15969586

SCHEMBL15969586

NC(=O)C1=C(C(N)=O)C(Cc2ccncc2)Cc2cc(O)ccc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 10/20 0.67
CYP11B2 P19099 1/20 0.50
CYP26A1 O43174 4/20 0.41
MEN1 O00255 2/20 0.41
GLA P06280 2/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
NR1I2 O75469 1/20 0.41
GMNN O75496 1/20 0.41
USP2 O75604 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
HSP90AA1 P07900 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15970366 0.92 CYP19A1 (0.56) CYP19A1CYP11B2CYP26A1PDE4D
SCHEMBL15969572 0.86 CYP19A1 (0.49) CYP19A1CYP26A1MEN1GLAKMT2A
SCHEMBL15969573 0.80 CYP19A1 (0.42) CYP19A1CYP11B2CYP26A1MEN1GLA
SCHEMBL8272615 0.67 CYP19A1 (1.00) CYP19A1CYP11B2CYP26A1
SCHEMBL15969815 0.67 MTNR1A (0.39) CYP19A1MEN1GLAKMT2AGAA
SCHEMBL20809838 0.66 CYP19A1 (0.68) CYP19A1CYP26A1MEN1GLAKMT2A
SCHEMBL8243133 0.64 CYP19A1 (0.66) CYP19A1PDE4D
SCHEMBL12306070 0.63 CYP19A1 (0.65) CYP19A1PDE4D
SCHEMBL8462840 0.62 CYP19A1 (0.60) CYP19A1CYP11B2CYP26A1MEN1KMT2A
SCHEMBL6378154 0.62 CYP19A1 (1.00) CYP19A1CYP26A1PDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, H1-3 CYP19A1 739/4885CYP11B2 848/4885CYP26A1 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.